

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Touyun Biotech Group Limited
透雲生物科技集團有限公司
(Incorporated in Bermuda with limited liability)
(Stock Code: 1332)

APPOINTMENT OF CHIEF EXECUTIVE OFFICER

APPOINTMENT OF CHIEF EXECUTIVE OFFICER

The board (the “**Board**”) of directors (the “**Directors**”) of Touyun Biotech Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Ms. Ha Amy (“**Ms. Ha**”) has been appointed as the chief executive officer of the Company with effect from 3 January 2022.

The biographical details of Ms. Ha is as follows:

Ms. Ha (Former name: Ha Man), aged 50, is appointed as the chief executive officer of the Company with effect from 3 January 2022. Ms. Ha has extensive experiences in the financial management and investment. From April 1998 to June 2014, she joined Bank of China (Hong Kong) Limited, her last position was assistant general manager in Corporate Business II at Corporate Banking and Financial Institutions. She was also Head of China Business within this period and she was mainly responsible for managing the business in China and major commodities transactions. From February 2015 to December 2021, she was a managing partner of Tenplus Venture Capital Management Company. She has extensive experiences in the corporate strategic development and operations.

Ms. Ha obtained her degree of Executive Master of Business Administration from the Hong Kong University of Science and Technology in 2009.

Ms. Ha has entered into a service contract with the Group for a term of 1 year from the date of appointment on 3 January 2022. She is entitled to have an annual emolument of HK\$3,000,000, which is determined by the Board with reference to her duties, responsibilities, remuneration policy of the Company and performance of the Company as well as the prevailing market conditions, and it shall be reviewed by the remuneration committee of the Board from time to time.

Save as disclosed above, as at the date of this announcement, Ms. Ha has confirmed that she: (i) has not held any position with the Group; (ii) has not held any other directorship in the last three years preceding the date of this announcement in public companies, the securities of which are listed on any securities market in Hong Kong or overseas; (iii) does not have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders of the Company; and (iv) does not have any information to be disclosed pursuant to any of the requirements under Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters in relation to the appointment of Ms. Ha that need to be brought to the attention of the shareholders of the Company.

As at the date of this announcement, Ms. Ha does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Board would like to extend its warm welcome to Ms. Ha for newly appointment as Chief Executive Officer of the Company.

By order of the Board
Touyun Biotech Group Limited
Wang Liang
Chairman

Hong Kong, 3 January 2022

As at the date of this announcement, the Board comprises the following directors:

Executive Directors

Mr. Wang Liang (*Chairman*)
Mr. Du Dong

Non-executive Directors

Mr. Chen Hui
Ms. Tian Yuze
Mr. Zhang Lele
Mr. Jia Wenjie

Independent non-executive Directors

Mr. Cheung Wing Ping
Mr. Ha Kee Choy Eugene
Mr. To Shing Chuen
Mr. Hu Guohua